[ Price : $8.95]
FDA seeks input on whether traditional statistical standards should be modified for rare disease clinical investigations, includin...[ Price : $8.95]
FDAs approval of Outlook Therapeutics Lytenava shows that the agencys willingness to accept one adequate and well-controlled trial...[ Price : $8.95]
AstraZeneca and Daiichi Sankyo says that Enhertu cut the risk of disease progression or death by 37% compared with pembrolizumab (...[ Price : $8.95]
FDA grants Pharming Group expanded approval for Joenja (leniolisib) tablets for treating activated phosphoinositide 3-kinase delta...[ Price : $8.95]
FDA extends by three months its review of an Exelixis NDA for zanzalintinib, in combination with atezolizumab, for treating patien...[ Price : $8.95]
Oncology Center of Excellence director Angelo de Claro says the center will build on initiatives established under longtime and fo...[ Price : $8.95]
A Sheppard analysis warns that regulated industry should expect closer scrutiny of statements about FDA interactions and broaden t...[ Price : $8.95]
A new report from the Association for Accessible Medicines calls for changes to FDA policies, patent law, pharmacy benefit manager...